Recent News

AUA 2021: Interim Analysis of Novel Immunotherapy for BCG-Unresponsive Bladder Cancer

ESMO 2021: Bladder Preservation in Older Patients With Muscle-Invasive Bladder Cancer

AUA 2021: Long-Term Analysis of UGN-101 in Upper Tract Urothelial Carcinoma

AUA 2021: Initial Study Findings With Large Surface Area Microparticle Docetaxel in Bladder Cancer

Is Aspirin Intake Associated With Risk of Bladder Cancer or Its Prognosis?

Muscle-Invasive Bladder Cancer: Comparing Trimodal Therapy and Radical Cystectomy

Pembrolizumab Receives Full FDA Approval for Certain Patients With Advanced Urothelial Carcinoma

Novel Approach to Detecting PD-L1 in the Urine of Patients With Bladder Cancer

FDA Approves Nivolumab as First Adjuvant Treatment for High-Risk Urothelial Carcinoma

Can Dietary Tomato Intake Influence the Risk of Bladder Cancer?

Urothelial Carcinoma: Prognostic Factors Associated With Immune Checkpoint Inhibitors

Atezolizumab in Resistant Advanced Urothelial Cancer: Prognostic Significance of Pretreatment Factors

Adding Atezolizumab to Chemotherapy for Muscle-Invasive Bladder Cancer

Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma

Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy

A New Model Under Study to Predict Staging of Upper Tract Urothelial Cancer

Enfortumab Vedotin-ejfv Receives FDA Approval for Advanced Urothelial Carcinoma

Can Circulating Tumor Cells Predict Need for Neoadjuvant Chemotherapy in Bladder Cancer?

Bladder-Preserving Combined-Modality Therapy for Localized Muscle-Invasive Bladder Cancer

ASCO 2021: Chemotherapy Prior to Cystectomy for Older Patients With Muscle-Invasive Bladder Cancer

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: Changing the Treatment Game

ASCO 2021: INDUCE-1 Trial of Feladilimab Plus Pembrolizumab in Urothelial Carcinoma

ASCO 2021: Neoadjuvant Therapy and Transurethral Resection of Bladder Cancer

ASCO 2021: Post Hoc Subgroup Analyses With Avelumab in Advanced Urothelial Carcinoma

ASCO 2021: 5-Year Update on Pembrolizumab for Advanced Urothelial Cancer

ASCO 2021: KEYNOTE-052 Survival Update on First-Line Pembrolizumab in Advanced Urothelial Cancer

ASCO 2021: Bladder-Sparing Combination Therapy Under Study in Muscle-Invasive Urothelial Cancer

Bladder Cancer Footprint? Fox Chase Researcher Awarded NIH Grant for Diagnostic Urine Test

Multimodal Imaging Strategy Under Study in Urothelial Cell Carcinoma

TROPHY-U-01 Supports Use of Sacituzumab Govitecan-hziy in Metastatic Urothelial Carcinoma

Lymphocyte-to-Monocyte Ratio: Prognostic Marker in Bladder Cancer?

Can Targeting APE1 and SSRP1 Improve Survival in Muscle-Invasive Bladder Cancer?

DNA Methyltransferase Inhibitor Under Study in Cisplatin-Resistant Urothelial Carcinoma

Update on Potential Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis

First-Line Treatments in Metastatic Urothelial Cancer: Real-World Decision-Making

Priority Review Accepted by FDA for Nivolumab in Adjuvant Treatment of Muscle-Invasive Urothelial Cancer

Neoadjuvant Cabazitaxel Plus Cisplatin in Muscle-Invasive Bladder Cancer

Long-Term Outcomes and Costs of BCG Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer

Metastatic Distribution of Urothelial Cancer: Differences Related to Age and Sex

Two sBLAs Accepted by FDA for Enfortumab Vedotin-ejfv in Urothelial Cancer

AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer

Sacituzumab Govitecan-hziy Granted Accelerated Approval for Advanced Urothelial Carcinoma

Is Adjuvant Atezolizumab Safe and Effective in Muscle-Invasive Urothelial Cancer?

How Metabolic Factors May Influence Bladder Cancer Risk and Mortality

Potential Factors Linked to Patient Discontinuation of Therapy for Bladder Cancer

Adjuvant Durvalumab for Localized Urothelial Cancer

FDA Grants Two New Breakthrough Device Designations for MRD Testing